Magnesium%252520sulfate

# Magnesium Sulfate ## Overview Magnesium sulfate is an essential electrolyte used for the treatment of hypomagnesemia and various obstetric and cardiac conditions. It acts as an anticonvulsant by depressing the central nervous system and blocking peripheral neuromuscular transmission. ## Primary Indications * **Hypomagnesemia:** Replacement of magnesium deficit. * **Eclampsia/Pre-eclampsia:** Prevention and control of seizures. * **Torsades de Pointes:** Acute management of polymorphic ventricular tachycardia associated with QT prolongation. * **Severe Asthma:** Adjunctive therapy for acute exacerbations unresponsive to first-line agents. * **Preterm Labor:** Neuroprotection (fetal/neonatal). ## Adult Dosing * **Hypomagnesemia (Mild):** 1–2 g IV or IM every 6 hours for 4 doses. * **Hypomagnesemia (Severe/Symptomatic):** 2–4 g IV over 15–30 minutes, followed by a continuous infusion (e.g., 5–10 g over 24 hours). * **Eclampsia:** Loading dose of 4–6 g IV over 15–20 minutes, followed by maintenance infusion of 1–2 g/hour. * **Torsades de Pointes:** 2 g IV bolus over 5–20 minutes; may repeat once if palpitations persist. * **Severe Asthma:** 2 g IV over 20 minutes (typically single dose). ## Pediatric Dosing * **Hypomagnesemia:** 25–50 mg/kg/dose IM or IV (slowly) every 4–6 hours as needed. * **Severe Asthma:** 25–50 mg/kg/dose (max 2 g) IV infused over 20 minutes. * *Note: Always verify pediatric dosing against weight-based institutional protocols.* ## Dose Adjustments * **Renal Impairment:** Requires significant caution and dose reduction; magnesium is renally excreted. Monitor serum levels frequently and decrease rate/frequency in patients with CrCl <30 mL/min. ## Contraindications * Myasthenia gravis (increased risk of neuromuscular blockade). * Heart block or myocardial damage (significant). * Severe renal impairment (CrCl <20 mL/min). ## Adverse Effects * **Common:** Flushing, sweating, burning sensation at injection site, hypotension. * **Serious (Magnesium Toxicity):** Loss of deep tendon reflexes (first sign, ~7–10 mEq/L), respiratory depression, bradycardia, hypotension, complete heart block, cardiac arrest. * **Antidote:** Calcium gluconate 1g IV for severe toxicity. ## Key Drug Interactions * **Neuromuscular Blockers:** Potentiates effect; use with extreme caution. * **Aminoglycosides:** May exacerbate neuromuscular blockade. * **Digitalis Glycosides:** Use caution; sudden shifts in calcium/magnesium levels may precipitate digitalis toxicity. ## Monitoring * **Serum Magnesium:** Target 1.5–2.0 mEq/L for replacement; higher levels for eclampsia. * **Clinical Efficacy/Toxicity:** Assess hourly during infusion: * Deep tendon reflexes (must be present). * Respiratory rate (must be >12–16 breaths/min). * Urine output (must be >30 mL/hour or 100 mL/4 hours). ## Clinical Pearls * **Administration:** Slow IV infusion is mandatory to prevent hypotension and cardiac collapse. * **Route:** IM injection is painful and should be reserved only when IV access is impossible. * **Site:** If administering peripheral IV, use a large vein to minimize irritation. * **Protocol Dependence:** Dosing for eclampsia, neuroprotection, and cardiac arrest varies significantly by institutional protocol and clinical context. *** *Disclaimer: This information is for educational purposes only. Always consult current, institutional-specific guidelines and verify all dosages with the latest prescribing information or a qualified pharmacist before administration.*